

---

*primary studies - published RCT*

## **Nebulized hypertonic saline containing hyaluronic acid improves tolerability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone: a prospective, randomized, double-blind, controlled study.**

**Code:** PM22968159

**Year:** 2012 **Date:** 2012

**Author:** Furnari ML

### **Study design (if review, criteria of inclusion for studies)**

prospective, randomized, double-blind, parallel-group, controlled study

### **Participants**

patients with cystic fibrosis and lung disease

### **Interventions**

a hypertonic saline solution containing hyaluronic acid (Hyaneb) versus standard hypertonic saline

### **Outcome measures**

tolerability of hypertonic saline

### **Main results**

The results showed that nebulized Hyaneb was more effective in reducing the need for beta(2) bronchodilators and caused a significant reduction in the incidence of adverse effects compared with nebulized hypertonic saline solution alone. Its safety profile indicates that Hyaneb can be used for the treatment of lung disease in cystic fibrosis.

<http://dx.doi.org/10.1177/1753465812458984>

### **See also**

Ther Adv Respir Dis. 2012 Sep 11.

### **Keywords**

Adolescent; Child; hyaluronic acid; hydration; Hypertonic Solutions; Inhalation OR nebulised; pharmacological\_intervention; Airway clearance drugs -expectorants- mucolytic- mucociliary-; Respiratory System Agents;